Preventive fremanezumab effective against episodic migraine

  • Dodick DW & al.
  • JAMA
  • 15 May 2018

  • curated by Kelli Whitlock Burton
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preventive treatment with subcutaneous fremanezumab significantly reduced the number of migraine headache days compared with placebo in patients with episodic migraine in whom multiple medication classes had not previously failed.
  • A monthly dosage and a single higher dosage designed for a quarterly dosing regimen were both effective at reducing migraine days.  

Why this matters

  • Preventive treatment is recommended for people who have at least 4 episodes per month of episodic migraine, which is the most common type of migraine.

Study design

  • Randomized, placebo-controlled, parallel-group trial of 875 patients (fremanezumab monthly dosing, n=290; single higher dose, n=291; placebo, n=294) with episodic migraine.
  • Patients underwent a screening visit, 12-week treatment period, and final evaluation at 12 weeks.
  • Funding: Teva Pharmaceuticals.

Key results

  • Mean monthly migraine days were 8.9 in the monthly dosing, 9.2 in single higher dose, and 9.1 in placebo groups.
  • At 12 weeks, mean migraine days per month decreased to 4.9 days in monthly dosing group, 5.3 days in single higher dose, and 6.5 days in placebo groups.
  • A statistically significant difference observed with monthly dosing vs placebo of –1.5 days (P<.001 and single higher dose vs placebo of days>

Limitations

  • Short follow-up duration.

Coauthored with Anand Ramanathan, PharmD

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit